LEADER 02843nam  22005895u 450 
001 9910156320503321
005 20211006145206.0
010   $a9783318032222
010   $a3318032220
035   $a(CKB)3780000000101874
035   $a(OCoLC)967184230
035   $a(SZ-BaSKA)222880
035   $a(MiAaPQ)EBC31865652
035   $a(Au-PeEL)EBL31865652
035   $a(EXLCZ)993780000000101874
100   $a20211006d1995      uy         0
101 0 $aeng
135   $aurunu|||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aOral Cephalosporins / $f editor, R.C. Moellering Jr
205   $a1st ed.
210   $aBasel : $cS. Karger, $d1995
215   $a1 online resource (X + 190 pages) : $c  13 figures, 44 tables
225 0 $aAntibiotics and Chemotherapy, $x1662-2863 ; $vVol.47
311 08$a9783805561631 
311 08$a3805561636 
330   $aThis volume provides an excellent survey of the chemistry, microbiology, pharmacology and clinical use of the oral cephalosporins in general and the newer agents in particular. The cephalosporins have long provided satisfactory treatment for many disorders without causing serious side effects; and over the past fifty years forms with different antimicrobial, pharmacologic and toxicologic properties have been developed.  Despite the broad spectrum of their activity against a large variety of gram-positive and gram-negative bacteria, the third-generation oral cephalosporins including the prodrug esters do not work against Pseudomonas aeruginosa, methicillin-resistant staphylococci, enterococci or Bacteroides species. Many, however, are suitable for treating infections of the respiratory and urinary tracts and of the skin and its structure, as well as certain sexually-transmitted diseases. Authors consider other possible uses, against multi-resistant Enterobacteriaceae for instance, but also point out the limitations of the oral cephalosporins. For those working in the fields of infectious disease, bacteriology, chemotherapy, pharmaceutics and pharmacokinetics, this book is a valuable source of authoritative information.
410  0$aIssn Series
606   $aPharmacology
606   $aInfectious Diseases
606   $aBacteriology
606   $aChemotherapy
606   $aPharmaceutics
606   $aPharmacokinetics
615 14$aPharmacology
615 14$aInfectious Diseases
615 24$aBacteriology
615 24$aChemotherapy
615 24$aPharmaceutics
615 24$aPharmacokinetics
676   $a615.5/8 s
676   $a615/.32924
700   $aMoellering Jr$b R.C
701   $aMoellering$b Robert C$01232161
801  0$bUKSKG
801  1$bUKSKG
906   $aBOOK
912   $a9910156320503321
996   $aOral Cephalosporins$92860978
997   $aUNINA